Yes, there is now a cure for sickle cell anemia. Two options exist: bone marrow transplants, which have been curing patients for decades, and gene therapy, which became available in December 2023 when the FDA approved two treatments. Both approaches can eliminate sickle cell crises entirely, but each comes with significant tradeoffs in terms of risk, cost, and eligibility.
How Bone Marrow Transplants Cure Sickle Cell
A bone marrow transplant replaces the stem cells that produce sickle-shaped red blood cells with healthy ones from a donor. When it works, the new marrow takes over blood production permanently, and the disease is gone. This has been a proven cure since the 1980s, though for most of that time it was limited to children who had a fully matched sibling donor, which only about 15 to 20 percent of patients do.
The field has expanded significantly. Newer approaches allow transplants from half-matched family donors (a parent, for example), which dramatically widens the donor pool. A multi-center clinical trial of this technique in young adults with sickle cell disease, with a median age of about 23, reported two-year event-free survival of 88% and overall survival of 95%. A similar study from the Vanderbilt consortium in 70 patients found 83% event-free survival and 94% overall survival at two years. These are strong numbers, though the procedure still carries real risks: infections are the primary danger, and the conditioning chemotherapy needed to prepare the body can affect fertility, particularly in patients over 30.
Two Gene Therapies Now Approved
In December 2023, the FDA approved Casgevy and Lyfgenia, two gene therapies for sickle cell disease. Both are approved for patients 12 and older who have a history of recurring pain crises. They work differently from each other, but the basic concept is the same: your own stem cells are removed, genetically modified in a lab, and then infused back into your body.
Casgevy uses CRISPR gene editing to disable a genetic switch that normally shuts off fetal hemoglobin production after infancy. Fetal hemoglobin is a form of the oxygen-carrying protein that doesn’t sickle. By reactivating it, the therapy floods the bloodstream with healthy hemoglobin that prevents red blood cells from deforming. Research has shown that the levels of fetal hemoglobin achieved through this approach are high enough to stop the sickling process.
Lyfgenia takes a different approach, using a modified virus to deliver a functional copy of the hemoglobin gene directly into the patient’s stem cells. Rather than reactivating an old gene, it adds a new, working version.
What the Treatment Process Looks Like
Gene therapy for sickle cell is not a quick fix. The full process spans several months and involves a serious physical toll. Understanding the timeline helps set realistic expectations.
First, your stem cells are collected over a period of roughly six to eight weeks, which includes a short hospital stay of one to three days. Those cells are sent to a lab for genetic modification, which can take additional weeks or months. Before receiving the modified cells back, you undergo conditioning: high-dose chemotherapy delivered through an IV over about a week. This wipes out the existing bone marrow to make room for the corrected cells. It also temporarily destroys your immune system.
After the modified cells are infused, you’ll stay in a protective hospital room for about a month to reduce infection risk while your immune system is suppressed. The initial recovery period lasts roughly 100 days from the infusion date. During this time, your body is rebuilding its blood and immune system from scratch. It’s a demanding process, similar in intensity to what cancer patients experience during a bone marrow transplant.
Eligibility and Insurance Barriers
Not everyone with sickle cell disease qualifies for gene therapy right now. The FDA approval covers patients 12 and older with documented recurring pain crises. In practice, insurance companies have added their own restrictions on top of the FDA criteria.
A review of the five largest U.S. health insurers found that all five require patients to have at least two documented pain crises per year for the previous two years. Three of the five require that the patient be eligible for a stem cell transplant but unable to find a matched donor. Four of the five require that patients have tried and failed at least one medication first. These layered requirements mean that even patients who meet the FDA’s criteria may face denials or delays.
Medicaid covers gene therapy for sickle cell disease, but individual states can impose their own limits through prior authorization and other controls. The Centers for Medicare and Medicaid Services has created a voluntary program for states and manufacturers to use outcome-based payment arrangements, which ties reimbursement to whether the therapy actually works for a given patient.
The Cost Problem
Each gene therapy carries a list price of over $2 million for a one-time treatment. Medicare has approved add-on payments up to $2.325 million for Lyfgenia and $1.65 million for Casgevy in fiscal year 2025. These are among the most expensive therapies ever approved.
The price reflects the complexity of the treatment (each patient’s cells are individually modified) and the one-time nature of the cure. But it creates a significant access gap. Sickle cell disease disproportionately affects Black Americans, many of whom are covered by Medicaid, and state Medicaid programs are still figuring out how to finance treatments at this price point. The gap between having an approved cure and being able to actually receive it remains one of the biggest challenges in sickle cell care.
What’s Coming Next
The current gene therapies require the same harsh chemotherapy conditioning as a bone marrow transplant, which is a major barrier for many patients. Researchers at the University of Washington and Fred Hutch Cancer Center are developing methods to edit the sickle cell gene directly inside the body, without removing stem cells at all. Their approach uses a modified virus to deliver a “base editor” that swaps out a single letter of DNA without cutting the strand. If this works in humans, it could eliminate the need for chemotherapy conditioning entirely, making a cure far more accessible. That work is still in early stages, but it represents the clearest path toward a treatment that could reach the millions of people worldwide living with sickle cell disease.